wire - news in brief

« BACK

Life Sciences



Results 1 - 50 of 658.
1 2 3 4 5 ... 14 Next »

Life Sciences
23.10.2017
Sleepwalkers are better at automatic walking
Sleepwalkers who are awake may have a multi-tasking advantage over non-sleepwalkers, according to recent research that uses virtual realilty. Try counting backwards from 200 in steps of 7 while walking en-route to your favourite café. Chances are, you will slow down or even freeze mid-stride, unless you are a sleepwalker.
Life Sciences - Microtechnics/Electroengineering
20.10.2017
Embark on a cognitive revolution at EPFL
Use your brainwaves to control the workings of a machine and contribute to science at EPFL ArtLab's next art-science exhibition, "Mental Work" from October 27 th - February 11 th , 2018.
Medicine/Pharmacology - Life Sciences
16.10.2017
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to
Physics/Materials Science - Life Sciences
09.10.2017
Life Sciences
05.10.2017
Physics/Materials Science - Life Sciences
04.10.2017
Highlighting the significance of structural analysis of biomolecules
The Nobel Prize in Chemistry 2017 has been awarded to Jacques Dubochet of Switzerland, U.S.-based German scientist Joachim Frank, and Richard Henderson of the United Kingdom for the development of structural analysis of single biological molecules by means of cryo-electron microscopy.
Life Sciences - Medicine/Pharmacology
03.10.2017
Clumps as temporary storage
Clumps as temporary storage
Researchers at ETH have discovered that the formation of protein aggregates in yeast cells is reversible. This casts new light on human diseases that can be attributed to certain protein aggregates. Protein aggregates have a bad reputation. A number of human diseases, especially those of the nervous system, such as Alzheimer's, Parkinson's, or amyotrophic lateral sclerosis (ALS), are due to the clumping of degenerate proteins in nerve cells, creating aggregates that the cells cannot dissolve.
Environment/Sustainable Development - Life Sciences
29.09.2017
5 professors appointed
At its meeting of 28 September 2017, the ETH Board appointed 5 new professors upon application of ETH Zurich President Lino Guzzella.
Medicine/Pharmacology - Life Sciences
28.09.2017
Novartis and UC Berkeley collaborate to tackle ’undruggable’ disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer   New Novartis-Berkeley Center for Proteomics and Ch
Life Sciences - Medicine/Pharmacology
25.09.2017
New regulator for liver regeneration
New regulator for liver regeneration
By performing large-scale proteomics analysis of liver proteins, ETH researchers have discovered a protein that is essential for liver regeneration. They have also figured out the mechanism of the protein's function. The liver is a wonderful thing: it's the only organ able to fully regenerate with no scar tissue formation, even after major injury.
Life Sciences - Mathematics
24.09.2017
A brain-system that builds confidence in what we see, hear and touch
A brain-system that builds confidence in what we see, hear and touch
A series of experiments at EPFL provide conclusive evidence that the brain uses a single mechanism (supramodality) to estimate confidence in different senses such as audition, touch, or vision. The study is published in the Journal of Neuroscience. Behavioral scientists and psychologists use the term "metacognition" to describe our ability to access, report and regulate our own mental states: "thinking about thinking", "knowing about knowing" "being aware about being aware", are all higher-order cognitive skills that fit this category.
Medicine/Pharmacology - Life Sciences
22.09.2017
Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche receives European approval for Actemra /RoActemra in giant cell arteritis Actemra/RoActemra is the first therapy approved for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The approval was based on the outcome of the phase III GiACTA study Roche announced today that the European Commission (EC) has approved Actemra /RoActemra (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition.
Physics/Materials Science - Life Sciences
20.09.2017
X-ray and neutron imaging for palaeontologists and archaeologists
The interior of fossils and artefacts that are hundreds, thousands and yes, sometimes millions of years old can be examined at two PSI research facilities. A conversation with Federica Marone and Eberhard Lehmann, who are opening a new view into the past with their methods. Ms. Marone, Mr. Lehmann  -  palaeontologists and archaeologists regularly come to you to look inside fossils and ancient objects with your non-destructive analysis methods.
Medicine/Pharmacology - Life Sciences
20.09.2017
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Significant overall surviv
Chemistry - Life Sciences
19.09.2017
Nanocapsules Enable Cell-Inspired Metabolic Reactions
Nanocapsules Enable Cell-Inspired Metabolic Reactions
Researchers at the University of Basel succeeded in developing capsules capable of producing the bio-molecule glucose-6-phosphate that plays an important role in metabolic processes. The researchers were able to produce the metabolite in conditions very similar to the biochemical reaction inside natural cells.
Medicine/Pharmacology - Life Sciences
16.09.2017
Novartis’ Xolair confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled   Should a treatment pause be necessary, data showed almost 90% of chronic spontaneous urticaria (CSU) patients - previously well controlled - regained effective symptom control within 12 weeks of re-treatment on Xolair   Previous studies have shown that inadequately controlled CSU has a major impact on sleep, social l
Medicine/Pharmacology - Life Sciences
14.09.2017
Increase of antibiotic resistance - Antibiotic Awareness Week highlights the risks
Bern, 14.09.2017 - The global fight against antibiotic resistance is ramping up. The World Health Organization has launched an Antibiotic Awareness Week, which will be running for the first time in Switzerland from 13 to 19 November 2017.
Medicine/Pharmacology - Life Sciences
14.09.2017
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira * safety and efficacy profile Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases Holzkirchen, Septem
Medicine/Pharmacology - Life Sciences
13.09.2017
Vessels that help cancers spread can also boost cancer immunotherapy
Vessels that help cancers spread can also boost cancer immunotherapy
Scientists from Switzerland and the US have shown that lymphatic vessels can enable both metastasis and T-cell invasion, opening new paths for cancer immunotherapy. Many cancers, such as melanoma, are known to metastasize and spread by expanding nearby lymphatic vessels. This process, lymphangiogenesis, also helps the tumor evade the patient's own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of patients.
Medicine/Pharmacology - Life Sciences
12.09.2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our
Medicine/Pharmacology - Life Sciences
09.09.2017
Novartis presents new data at EURETINA 2017 confirming Lucentis efficacy and durability vs aflibercept
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD   Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Novartis, the global leader in ophthalmology, today reported new data confirming Lucentis (ranibizumab) efficacy and durability in patients with nAMD at the 17 th EURETINA Congress in Barcelona, Spain (September 7-10, 2017).
Medicine/Pharmacology - Life Sciences
08.09.2017
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for measuring tumour mutational burden Two prospective studies underway to assess the potential of tumour mutational burden to predict response to certain cancer immunotherapies Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) Congress from 8-12 September 2017 in Madrid, Spain.
Medicine/Pharmacology - Life Sciences
07.09.2017
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need   Dedicated cardiovascular safety study reaffirmed placebo-like tolerability of erenumab as seen consisten
Medicine/Pharmacology - Life Sciences
06.09.2017
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche today announced results from the global phase III ALUR study showing that Alecensa significantly reduc
Medicine/Pharmacology - Life Sciences
05.09.2017
Tuberculosis Research Against "Super Resistant Bacteria"
To fall ill from tuberculosis remains a great danger. A research team led by cell biologist Sébastien Gagneux at the Swiss Tropical and Public Health Institute (Swiss TPH) examines the antibiotic resistance mechanisms of Mycobacterium tuberculosis.
Medicine/Pharmacology - Life Sciences
05.09.2017
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a   There is a significant unmet need for safe and effective MS treatments for children and adolescents, for whom there are no specifically approved disease-modifying therapies   Children and adolescents living with MS face physical and cognitive disability that severely limits their ability to go about daily activities, such as going to school     PARADIGMS is a first of its kind study in pediatric MS.
Life Sciences - Environment/Sustainable Development
05.09.2017
Combating Japanese Beetles with Fungi
Zurich-Reckenholz, 05.09.2017 - In June of this year, the Japanese beetle (Popillia japonica) was detected for the first time in Switzerland, in the canton of Ticino. Considered to be a quarantine pest, it is subject to obligatory control. Agroscope researchers are testing whether this quarantine pest can be controlled with fungi that are effective against May and June beetles.
Life Sciences
05.09.2017
First Detailed Decoding of Complex Finger Millet Genome
First Detailed Decoding of Complex Finger Millet Genome
For many poor farmers in India and Africa, finger millet is a major staple food. The crop species is not only a rich source of minerals like calcium, iron, magnesium and zinc, and it contains many vitamins and essential amino acids.
Physics/Materials Science - Life Sciences
04.09.2017
Like a Revolving Door: How Shuttling Proteins Operate Nuclear Pores
Like a Revolving Door: How Shuttling Proteins Operate Nuclear Pores
Nuclear pore complexes are tiny channels where the exchange of substances between the cell nucleus and the cytoplasm takes place. Scientists at the University of Basel report on startling new research that might overturn established models of nuclear transport regulation. Their study published in the Journal of Cell Biology reveals how shuttling proteins known as importins control the function of nuclear pores - as opposed to the view that nuclear pores control the shuttling of importins.
Life Sciences - Arts and Design
31.08.2017
Artists Target Ibexes
Artists Target Ibexes
The video and sound installations, sculptures, and pictures on display at the exhibition aim to build new bridges between art and the natural sciences.
Medicine/Pharmacology - Life Sciences
30.08.2017
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice First-in-clas
Life Sciences - Medicine/Pharmacology
30.08.2017
UZH Life Sciences Fund Invests in First Spin-off
UZH Life Sciences Fund Invests in First Spin-off
CUTISS is a company with a vision: To use personalized skin grafts to heal people all over the world with skin defects, including burn victims.
Life Sciences
28.08.2017
A drone to rescue fawns
A drone to rescue fawns
Using a thermal camera mounted on a drone, an EPFL student has found a way to spot fawns before the harvester passes through.
Medicine/Pharmacology - Life Sciences
28.08.2017
Chronic Lack of Sleep Increases Risk-Seeking
Chronic Lack of Sleep Increases Risk-Seeking
Young adults have a natural sleep requirement of about 9 hours a day on average, older adults 7.5 hours.
Medicine/Pharmacology - Life Sciences
27.08.2017
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a long-established hypothesis from pre-clinical models
Medicine/Pharmacology - Life Sciences
24.08.2017
Novartis Kisqali (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor Approval is based on
Life Sciences - Physics/Materials Science
22.08.2017
Treating arthritis with algae
Researchers at ETH Zurich, Empa and the Norwegian research institute SINTEF are pursuing a new approach to treating arthritis.
Medicine/Pharmacology - Life Sciences
22.08.2017
New Test for Rare Immunodeficiency
Researchers at the University of Basel have developed a test to quickly and reliably diagnose a rare and severe immune defect, hepatic veno-occlusive disease with immunodeficiency. They reported on their findings in the Journal of Clinical Immunology. Rare diseases are often only diagnosed very late, especially since in many cases, diagnostic tests are not available or are only available in a few laboratories.
Life Sciences - Medicine/Pharmacology
21.08.2017
Basel Life: A Showcase for Europe's Life Sciences
Basel Life: A Showcase for Europe’s Life Sciences
Basel unites many strengths in life sciences: a strong university, strong industry and strong scientists.
Life Sciences - Medicine/Pharmacology
21.08.2017
Fundamentals of life: How centrosomes direct early embryos
Fundamentals of life: How centrosomes direct early embryos
Summer Series: Sarah Herrman is visiting Pierre Gönczy's lab at EPFL from the University of California, Santa Cruz.
Medicine/Pharmacology - Life Sciences
17.08.2017
Hemorrhagic Fevers: Countering Inflammation to Prevent Circulatory Failure
Hemorrhagic fevers are severe viral diseases that are often fatal. Researchers from the University of Basel have now identified messenger substances of the immune system, which in infected mice lead to the development of shock. These results, published in the scientific journal Cell Host & Microbe, open up new possibilities for the development of life-saving therapies.
Environment/Sustainable Development - Life Sciences
02.08.2017
Light pollution as a new threat to pollination
Light pollution as a new threat to pollination
Media releases, information for representatives of the media Media Relations (E) Artificial light disrupts nocturnal pollination and leads to a reduced number of fruits produced by the plant. This loss of night time pollination cannot be compensated by diurnal pollinators. The negative impact of artificial light at night on nocturnal pollinators might even propagate further to the diurnal community, as ecologists of the University of Bern were able to show.
Medicine/Pharmacology - Life Sciences
27.07.2017
Malaria Already Endemic in the Mediterranean by the Roman Period
Malaria Already Endemic in the Mediterranean by the Roman Period
Even today, Malaria is one of the greatest medical challenges worldwide, killing hundreds of thousands of people every year. In the past, people have adapted to the threat of malaria in various ways. These methods range from interventions in the environment like draining swamps, to genetic adaptations in the human body.
Life Sciences - Social Sciences
26.07.2017
Neolithic Farmers Practiced Specialized Methods of Cattle Farming
Neolithic Farmers Practiced Specialized Methods of Cattle Farming
Swiss farmers practiced various different methods of animal farming as early as 5,400 years ago, as demonstrated by a study by researchers from the University of Basel, as well as research institutions from Germany and the UK. The study focused on the settlement Arbon Bleiche 3 on the south bank of Lake Constance.
Medicine/Pharmacology - Life Sciences
21.07.2017
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis If approved, Actemra/RoActemra would be the first therapy for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The positive opinion is based on the outcome of the phase III GiACTA study Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positi
Medicine/Pharmacology - Life Sciences
21.07.2017
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Recommendation ba
Life Sciences - Medicine/Pharmacology
20.07.2017
Innate Reaction of Hematopoietic Stem Cells to Severe Infections
If severe infections result, the body must form more white blood cells to fight off infectious agents. Hematopoietic stem cells in the bone marrow are responsible for their production. These cells, which renew themselves throughout a person's lifetime, form all cells of the hematopoietic system.
Social Sciences - Life Sciences
18.07.2017
Low-dose diazepam can increase social competitiveness
Low-dose diazepam can increase social competitiveness
EPFL scientists have discovered how low-dose anxiolytics increase the social competitiveness of high-anxious individuals by boosting the energy output of mitochondria in an area of the mammalian brain that controls motivation and reward. Psychologists speak of anxiety in two forms: ‘state' anxiety, which refers to anxiety arising from a particular situation; and ‘trait' anxiety, which refers to anxiety as part of a person's overall personality.
Medicine/Pharmacology - Life Sciences
17.07.2017
Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia
Roche's OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for peop
Medicine/Pharmacology - Life Sciences
13.07.2017
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL Recommendation based on review of CTL019 r/r B
1 2 3 4 5 ... 14 Next »

 
 
Jobs listed on